0000905148-23-000957.txt : 20230921
0000905148-23-000957.hdr.sgml : 20230921
20230921163001
ACCESSION NUMBER: 0000905148-23-000957
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230919
FILED AS OF DATE: 20230921
DATE AS OF CHANGE: 20230921
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GOODMAN COREY S
CENTRAL INDEX KEY: 0001278411
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41799
FILM NUMBER: 231269404
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Adelman Robert J
CENTRAL INDEX KEY: 0001329161
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41799
FILM NUMBER: 231269405
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: VENBIO GLOBAL STRATEGIC GP III, L.P.
CENTRAL INDEX KEY: 0001869303
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41799
FILM NUMBER: 231269407
BUSINESS ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 415-800-0800
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: venBio Global Strategic Fund III, L.P.
CENTRAL INDEX KEY: 0001739920
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41799
FILM NUMBER: 231269408
BUSINESS ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 415-522-0100
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: VENBIO GLOBAL STRATEGIC GP III, LTD
CENTRAL INDEX KEY: 0001869300
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41799
FILM NUMBER: 231269406
BUSINESS ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCI
STATE: CA
ZIP: 94158
BUSINESS PHONE: 415-800-0800
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCI
STATE: CA
ZIP: 94158
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RayzeBio, Inc.
CENTRAL INDEX KEY: 0001825367
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5505 MOREHOUSE DRIVE, SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: (619) 937-2754
MAIL ADDRESS:
STREET 1: 5505 MOREHOUSE DRIVE, SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
form4.xml
X0508
4
2023-09-19
true
0001825367
RayzeBio, Inc.
RYZB
0001739920
venBio Global Strategic Fund III, L.P.
1700 OWENS STREET
SUITE 595
SAN FRANCISCO
CA
94158
true
0001869303
VENBIO GLOBAL STRATEGIC GP III, L.P.
1700 OWENS STREET
SUITE 595
SAN FRANCISCO
CA
94158
true
0001869300
VENBIO GLOBAL STRATEGIC GP III, LTD
1700 OWENS STREET
SUITE 595
SAN FRANCISCO
CA
94158
true
0001329161
Adelman Robert J
1700 OWENS STREET
SUITE 595
SAN FRANCISCO
CA
94158
true
0001278411
GOODMAN COREY S
1700 OWENS STREET
SUITE 595
SAN FRANCISCO
CA
94158
true
false
Common Stock
2023-09-19
4
C
0
3786957
A
3786957
D
Common Stock
2023-09-19
4
C
0
1123862
A
4910819
D
Common Stock
2023-09-19
4
C
0
247343
A
5158162
D
Series A Convertible Preferred Stock
2023-09-19
4
C
0
3786957
D
Common Stock
3786957
0
D
Series B Convertible Preferred Stock
2023-09-19
4
C
0
1123862
D
Common Stock
1123862
0
D
Series C Convertible Preferred Stock
2023-09-19
4
C
0
216127
D
Common Stock
247343
0
D
Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series A Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series A Preferred Stock had no expiration date.
Each share of Series B Convertible Preferred Stock (the "Series B Preferred Stock") was convertible into shares of Common Stock of the Issuer on a one-for-one basis. Upon the closing of the Issuer's initial public offering, the Series B Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series B Preferred Stock had no expiration date.
Each share of Series C Convertible Preferred Stock (the "Series C Preferred Stock") was convertible into shares of Common Stock of the Issuer on a one-for-1.14443753806379 basis. Upon the closing of the Issuer's initial public offering, the Series C Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Series C Preferred Stock had no expiration date.
These securities are held directly by venBio Global Strategic Fund III, L.P., a Cayman Islands partnership ("venBio III"). venBio Global Strategic GP III, L.P., a Cayman Islands partnership ("venBio GP") is the sole general partner of venBio III. venBio Global Strategic GP III, Ltd., a Cayman Islands company ("venBio Ltd") is the sole general partner of venBio GP. Robert Adelman and Corey Goodman, each a citizen of the United States (collectively, the "Directors") are each a director of venBio Ltd and may be deemed to share voting and dispositive power over the securities held directly by venBio III. Each of the Directors, together with venBio Ltd and venBio GP, disclaims beneficial ownership over the securities held directly by venBio III except to the extent of their pecuniary interest therein.
Dr. Aaron Royston serves as a member of the Issuer's board of directors and is a director of venBio Ltd. However, Dr. Royston disclaims beneficial ownership over the securities held by venBio III.
venBio Global Strategic Fund III, L.P., by: venBio Global Strategic GP III, L.P., its general partner, by: venBio Global Strategic GP III, Ltd., its general partner, by: /s/ David Pezeshki, as attorney-in-fact
2023-09-21
venBio Global Strategic GP III, L.P., by: venBio Global Strategic GP III, Ltd., its general partner, by: /s/ David Pezeshki as attorney-in-fact
2023-09-21
venBio Global Strategic GP III, Ltd., by: /s/ David Pezeshki, as attorney-in-fact
2023-09-21
Robert Adelman, by: /s/ David Pezeshki, as attorney-in-fact
2023-09-21
Corey Goodman, by: /s/ David Pezeshki, as attorney-in-fact
2023-09-21